PREX2

Across TCGA pan-cancer cohorts, PREX2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PREX2 data layer compared with 22 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher PREX2 Mutation is associated with better overall survival. In most high-consensus cancer types, elevated PREX2 expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCEC show a favorable association.

SKCM, ESCA, and UCEC are the cancer types where PREX2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.483	0.298	.001	18	view →
ESCA	OS	Median	All	0.195	0.872	<.001	12	view →
UCEC	DFS	Median	All	0.945	0.827	.027	6	view →
LIHC	OS	Median	II,III,IV	0.218	0.622	.029	3	view →
BRCA	OS	Median	III,IV	0.653	0.907	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PREX2–SKCM (OS)

Open the SKCM breakdown →